Concepedia

Publication | Open Access

Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–Resistant Patients: Recommendations and Evidence

DOIFull Paper Access

37

Citations

5

References

2010

Year

Jawaid Younus, S. Verma, Jacob Franek, N. Coakley
Current Oncology

Abstract

In the target population, sunitinib malate is the recommended option for second-line therapy of metastatic GIST.

References

YearCitations

Page 1